iShares Industrial Bond ETF ENGN 深 沪
等待开盘 09-08 09:30:00 美东时间
5.18
+0.180
+3.60%
华盛通- 最 高5.225
- 今 开5.00
- 成交量 12.52万股
- 最 低 4.815
- 昨 收 5.00
- 总市值 2.65亿
- 52周最高 11.00
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 2.65
- 委 比 -26.55%
- 总股本 5110.52万
- 历史最高 43.00
- 量 比 0.25
- 振 幅 8.20%
- 历史最低 2.65
- 每 手 1
- 风险率 1.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多enGene Holdings Reaches Target Enrollment Of 100 Patients For Pivotal Cohort Of Its Ongoing, Open-Label, Multi-Cohort Phase 2 LEGEND Trial Of Detalimogene Voraplasmid In Patients With High-Risk, NMIBC
Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achievedenGene plans to provide an update from LEGEND's pivotal cohort in 4Q 2025Biologic License Application (BLA) submission planned for
09-03 19:35
enGene Holdings Announces The U.S. FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Detalimogene Voraplasmid For Expedited Review In High-Risk, Non-Muscle Invasive Bladder Cancer
Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development toolsDesignation recognizes the potential of detalimogene to address significant unmet needenGene Holdings Inc.
06-25 20:12
enGene Holdings Reports Q2 2025 Financial Results
Engene Holdings Inc. ( ($ENGN) ) has released its Q2 earnings. Here is a breakd...
06-13 11:53
enGene Holdings Q2 EPS $(0.51) Misses $(0.49) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. This is a 34.21 percent decrease over losses of $(0.38) per share from
06-12 20:13
enGene Holdings Approves 2025 Employee Stock Purchase Plan
enGene Holdings ( ($ENGN) ) just unveiled an announcement. On June 10, 2025, en...
06-11 05:49
enGene Holdings CMO Resignation Announced
enGene Holdings ( ($ENGN) ) has provided an announcement. On June 3, 2025, Dr. ...
06-04 20:59
美股大行评级 | 美银证券：维持雅培"买入"评级，目标价从133美元升至150美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106501041932570625.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Roth MKM：维持CervoMed Inc.(CRVO)"买入"评级，目标价从7美元升至15美元</p> <p>• Oppenheimer：维持Trevi Therapeutics(TRVI)"跑赢大市"评级，目标价从
03-12 11:01
美股大行评级 | 潜在涨幅265%！Humacyte获机构上调目标价至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1078254829883351040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Benchmark：维持Humacyte(HUMA)"买入"评级，目标价从15美元升至17美元</p> <p>• Evercore ISI集团：维持BridgeBio Pharma(BBIO)"跑赢大市"评级，目标价从45
2024-12-24 09:30
enGene Holdings FY EPS $(1.46) Misses $(1.38) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.38) by 5.8 percent. This is a 99.03 percent increase over losses of $(151.22) per share from
2024-12-20 05:12
enGene Holdings: Strategic Differentiation Justifies Buy Rating Amidst Competitive Data
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rat...
2024-12-06 17:46
